296 PEGINTERFERON ALFA-2A (40KD) PLUS 800 OR 1000/1200 MG/DAY RBV IN G1 HIV-HCV-CO-INFECTED PATIENTS: EARLY RESPONSES TO TREATMENT AND PREDICTABILITY FOR SVR IN THE PARADIGM STUDY | Publicación